Related by context. All words. (Click for frequent words.) 75 tumor malignancies 71 hematologic tumors 70 HGS ETR2 70 ENMD # 69 metaglidasen 69 bavituximab monotherapy trial 69 evaluating tivozanib 67 hematological tumor 67 Aplidin 66 liposomal formulation 66 hematological cancers 66 AMPK activators 66 oral picoplatin 66 hematologic cancers 66 hematological indications 66 vinca alkaloid 66 dose escalation Phase 66 preclinical efficacy 65 AAG geldanamycin analog 65 xenograft models 65 aurora kinase inhibitor 65 selective kinase inhibitor 65 PRT# 65 radezolid 65 teriflunomide 65 alvespimycin 65 antimitotic 65 acyclovir Lauriad R 65 orally bioavailable 65 Carfilzomib 65 proteasome inhibitor 65 oral prodrug 65 HGS ETR1 65 peptide conjugated 65 TRAIL receptor antibodies 64 GLP toxicology studies 64 JAK inhibitors 64 TKM PLK1 64 CCX# 64 PDE4 inhibitor 64 MEK inhibitors 64 YONDELIS 64 telomerase inhibitor drug 64 Kahalalide F 64 novel DACH platinum 64 AKT inhibitor 64 sapacitabine CYC# 64 cMET 64 rxRNA 64 pathophysiological effects 64 orally administered inhibitor 64 PSMA ADC 64 HGS ETR1 mapatumumab 64 OMP #R# 64 pan HDAC inhibitor 64 CCR9 antagonist 64 RGB # 64 Omacetaxine 64 Panzem R NCD 64 HSP# inhibitor 64 HGS# 64 systemic RNAi therapeutic 63 BRAF inhibitor 63 novel nucleoside analog 63 KSP inhibitor 63 EndoTAG TM 63 tubulin inhibitor 63 Amrubicin 63 IMA# 63 AEG# 63 gamma secretase inhibitor 63 CYT# potent vascular disrupting 63 maximally tolerated dose 63 Phase Ib II 63 pegylated liposomal doxorubicin 63 epithelial tumors 63 demonstrated antitumor activity 63 anti EGFR antibody 63 delafloxacin 63 sunitinib malate 63 protein tyrosine phosphatase 1B 63 PEG SN# 63 Zoraxel TM 63 anionic backbone 63 indibulin 63 Tyrima 63 receptor tyrosine kinase inhibitor 63 nucleotide analog 63 antiangiogenic activity 63 volociximab 63 thalidomide Thalomid 63 multi kinase inhibitor 63 PI3K/mTOR 63 protein kinase inhibitor 63 PORxin TM 63 motesanib 63 small molecule tyrosine 63 targeted radiotherapeutic 63 CTAP# Capsules 63 dasatinib Sprycel 63 entinostat 63 JAK inhibitor 63 mertansine 63 Epothilones 63 potently inhibited 62 immune modulating 62 novel histone deacetylase 62 HCV protease 62 cleavable linker 62 CD# CEA 62 PD LID 62 MET inhibitor 62 midstage clinical 62 erlotinib Tarceva ® 62 pomalidomide 62 gemcitabine cisplatin 62 SinuNase ™ 62 ocular formulation 62 radiation sensitizer 62 CD# antibody [001] 62 Zemplar Capsules 62 Pharmos proprietary 62 docetaxel Taxotere R 62 sulfonylhydrazine class 62 Pertuzumab 62 novel VDA molecule 62 Zalypsis 62 Fc fusion protein 62 Panzem NCD 62 deforolimus 62 potent antiproliferative 62 MCSP respectively 62 selective agonist 62 Seliciclib 62 ongoing Phase 1b 62 cediranib 62 kidney urologic 62 investigational humanized monoclonal antibody 62 TBC# 62 palifosfamide Zymafos TM 62 Gleevec resistant 62 biologic therapeutics 62 anti leukemic 62 CA4P 62 YONDELIS R 62 GMX# 62 mGluR2 NAM 62 highly selective inhibitor 62 leading oral taxane 62 FOLFOX6 chemotherapy regimen 62 imatinib Gleevec ® 62 selective orally bioavailable 62 enzastaurin 62 amrubicin 62 CDK inhibitor 62 R#/MEM # 62 Deforolimus 62 phase peptide synthesis 62 lymphoid tumors 62 favorable pharmacokinetic profile 62 #ME# 62 fusion enhancers 62 immunotherapeutic agent 62 TOCOSOL Camptothecin 62 PSN# [002] 62 TLR9 agonist 62 agonistic human 62 Bevirimat 62 Cloretazine ® 62 IMiDs ® 62 oral Hsp# inhibitor 62 XL# anticancer compounds 62 selective inverse agonist 61 iniparib 61 Maribavir 61 IMiDs R 61 humanised monoclonal antibody 61 reversible inhibitor 61 nucleoside analogs 61 LymphoStat B belimumab 61 include 2D #.#D 61 OMP #M# 61 CBLC# 61 ZK EPO 61 orally bioavailable mimics 61 non nucleoside inhibitor 61 Xanafide 61 HQK 61 depsipeptide 61 anticancer activity 61 Zybrestat 61 selective estrogen receptor modulator 61 Pimavanserin 61 Solorel TM 61 alpha folate receptor 61 HCD# [002] 61 GRNVAC1 61 INCB# [001] 61 telomerase therapeutic 61 bortezomib Velcade 61 samalizumab 61 histone deacetylase inhibitor 61 epothilones 61 Vidofludimus 61 isoform selective 61 therapeutic monoclonal antibody 61 mGluR5 negative 61 gemcitabine Gemzar 61 Alocrest 61 nilotinib Tasigna ® 61 Zysolin TM 61 Azedra 61 torezolid 61 BAL# [001] 61 Symadex 61 JAK#/JAK# 61 trastuzumab DM1 T DM1 61 mda 7 61 Oral NKTR 61 ACAPODENE TM 61 ganetespib 61 EndoTAG 61 hA# 61 taxane refractory 61 candidate CRLX# 61 Panzem 61 GRN#L 61 Panzem R 61 VEGFR2 inhibitor 61 antisense inhibitors 61 drug zotarolimus 61 solid tumors ZYBRESTAT 61 hematologic malignancies 61 Preclinical studies suggest 61 HCV polymerase inhibitors 61 lipid nanoparticles 61 OncoVEX GM CSF 61 PI3K/Akt pathway inhibitor 61 corticosteroid dexamethasone 61 oxidative stress inducer 61 selective androgen receptor modulator 61 antiapoptotic 61 mitogen activated ERK kinase 61 Quinamed 61 Tarceva TM 61 Sym# 61 selective antagonist 61 vivo efficacy 61 Interferon alpha 61 delta isoform 61 IMiD 60 humanized antibody 60 ESBA# 60 phase IIa clinical 60 synthase TS 60 effector function 60 ruxolitinib 60 interferon gamma 1b 60 incyclinide 60 JAK2 inhibitors 60 HCV protease inhibitors 60 Sudhir Agrawal D.Phil 60 TELINTRA R 60 rALLy clinical trial 60 liquid phosphate fertilizers 60 oncology therapeutics 60 Fludara ® 60 Talabostat 60 tumor xenografts 60 vidofludimus 60 carbohydrate polymer 60 LymphoStat B TM 60 virus HCV protease inhibitor 60 Aflibercept 60 adecatumumab MT# 60 cytokine refractory 60 PRTX 60 TNF alpha selectively neutralizing 60 Vitaxin 60 CIMZIA ™ 60 hypoxia selective 60 selectively inhibits 60 allosteric modulator NAM 60 Onconase 60 sodium glucose cotransporter 60 urocortin 2 60 OHR/AVR# 60 targeting CD# 60 oral JAK1 60 Novolimus 60 plasma kallikrein inhibitor 60 Vicinium TM 60 AZD# ARRY # 60 selective modulator 60 BRIM3 60 peptibody 60 PRX# 60 GRN# 60 MEK inhibitor 60 Presents Preclinical 60 cathepsin K inhibitor 60 Virulizin ® 60 Alfacell proprietary ribonuclease 60 pertuzumab 60 anticoagulant reversing agent 60 nalbuphine ER 60 adipiplon 60 HER2 positive metastatic breast 60 ospemifene 60 XmAb# 60 solithromycin 60 sarcoma melanoma 60 cetuximab Erbitux R 60 Serdaxin ® 60 zotarolimus 60 CRLX# 60 GLPG# 60 Capesaris 60 3D wireframe surface 60 Ganetespib 60 vascular disrupting agent 60 IMC A# 60 Pharmacokinetic parameters 60 Phase #/#a trial 60 Litx 60 siRNAs targeting 60 novel peptide 60 vascular disrupting 60 Apoptone 60 TLR8 agonist 60 Rebif ® 60 NEUGENE antisense 60 fidaxomicin Phase 3 60 Fleximer 60 cyclin dependent kinases CDKs 60 Dasatinib 60 CR# vcMMAE 60 compound INCB# 60 VNP#M 60 vinorelbine tartrate 60 OXi# 60 PS# [001] 60 estramustine 60 HCV NS5B polymerase 60 trial evaluating PRX# 60 haematological cancers 60 Aurora kinase 60 davunetide intranasal AL 60 Annamycin 60 SAR# [004] 60 inhibits VEGF 60 anti fibrotic 60 MGd 60 HDACi 60 ALN TTR# 60 potent inhibitor 60 IMPDH inhibitor 60 Phase Ib study 60 IMP# 60 XOMA 3AB 60 Darinaparsin 60 humanized monoclonal antibodies 60 somatostatin analog 60 DXL# 60 XL# XL# XL# 60 antibody MAb 60 alkylating agent 60 picomolar 60 nanomolar potency 60 potent suppressor 60 lintuzumab SGN 60 Velcade bortezomib 60 CTA# Injection 60 bosutinib 60 darinaparsin ZIO 60 Solazed TM 60 lumiliximab 60 Blinatumomab 60 antisense inhibition 60 Exelixis compounds 60 cortisol synthesis 59 Anavex #-# 59 HuMax EGFr 59 axitinib 59 omacetaxine mepesuccinate 59 gastrin analogue TT 59 Tarvacin Anti Cancer 59 Omacetaxine mepesuccinate 59 histone deacetylase HDAC inhibitor 59 candidate TNFerade biologic 59 Hsp# Inhibitor 59 busulfan 59 MAGE A3 ASCI 59 farletuzumab 59 MT#/MEDI-# 59 initiated Phase Ib 59 A3 adenosine receptor 59 Telatinib 59 Liposomal 59 NOX E# 59 P#X# antagonist 59 Factor VIIa 59 Ambrisentan 59 delta opioid receptor 59 TG# [003] 59 essential thrombocythemia ET 59 radiotherapeutic 59 Orally administered 59 HuLuc# 59 EGS# 59 PEGylated interferon 59 ALN PCS 59 phase IIb clinical 59 Tykerb lapatinib 59 Akt inhibitor 59 IMiDs ® compound 59 IAP inhibitor 59 SNALP technology 59 Neulasta R 59 Rigel R# 59 DAVANAT R exhibits 59 Marqibo TM 59 Cannabinor 59 muscarinic receptor agonist 59 CORT # 59 Trofex TM 59 cytostatic 59 next generation URAT1 59 including eniluracil ADH 59 oral antiviral 59 bevacizumab Avastin ® 59 NXL# 59 2 methoxyestradiol #ME# 59 PORxin TM platforms 59 Bezielle 59 GVAX ® 59 Ceflatonin R 59 TAFA# 59 S1P antibody 59 mGluR5 antagonists 59 Beta catenin pathway 59 Phase #b/#a clinical 59 p# inhibitor 59 platinum chemotherapeutic 59 trastuzumab Herceptin R 59 OvaRex R 59 Mursuli nonetheless called 59 MEK inhibitor RDEA# 59 viral kinetics 59 Androxal TM 59 CB2 selective receptor agonist 59 lomitapide 59 oral proteasome inhibitor 59 sunitinib Sutent ® 59 XL# XL# 59 induced tumor regression 59 DNA intercalator 59 cytotoxics 59 ZOLINZA 59 Nanobody ® 59 K ras mutations 59 Angiolix 59 evaluating satraplatin 59 riociguat 59 nanomolar 59 microtubule inhibitor 59 Genz # 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 refractory chronic lymphocytic 59 PHX# 59 pharmacologically active isomer 59 Squalamine 59 ATL# [002] 59 ONCONASE R 59 Myocet 59 Aurora kinase inhibitor 59 MDS AML 59 preclinical compounds 59 tumor necrosis 59 siRNA binds 59 kinase inhibition 59 TELINTRA 59 PNP inhibitor 59 ABL inhibitor 59 5 FU leucovorin 59 generation proteasome inhibitor 59 Archexin 59 histone deacetylase HDAC 59 MOZOBIL 59 VDAs 59 VEGF receptors 59 Darusentan 59 phase IIb study 59 Guanilib 59 anticancer therapeutics 59 docetaxel Taxotere ® 59 castrate resistant prostate cancer 59 triphendiol 59 BiTE antibody 59 Janus Kinase 59 neuroprotective properties 59 Tezampanel 59 neratinib 59 Mipomersen 59 SUCCEED trial 59 AEGR 59 OncoVEX 59 immunomodulating 59 novel orally bioavailable 59 investigational therapies 59 Hedgehog inhibitor 59 Phase 2a trial 59 Lixivaptan 59 IgG1 antibodies 59 Anticalin ® 59 taxane resistant 59 omega interferon 59 FGFR 59 OvaRex ® MAb 59 Hsp# inhibition 59 pan histone deacetylase 59 alkylating 59 factor TNF 59 Iloperidone 59 HuMax CD#b 59 potent inhibition 59 ATL# [001] 59 RAV# 59 EndoTAG TM -1 59 photoprotective drug 59 potent antitumor activity 59 ISF# 59 MKC# MT 59 multitargeted 59 galiximab 59 Triapine R 59 accumulate preferentially 59 CINQUIL 59 Perifosine 59 TriRima 59 talabostat 59 5 HT2A serotonin 59 Presents Preclinical Data 59 PDE# inhibitors 59 mGluR5 NAM 59 fluoroquinolone antibiotic 59 purine analog 59 S/GSK# 59 oral beclomethasone dipropionate 59 AP# [003] 59 Solazed 59 non nucleoside HCV 59 ceftazidime 59 gefitinib Iressa 59 PSN# [001] 59 generation Hsp# inhibitor 59 Glufosfamide 59 monoclonal antibody MAb 59 IAP inhibitors 58 forodesine 58 Alzhemed TM 58 HCV RNA polymerase 58 vosaroxin 58 huC# DM4 58 acetylcholinesterase AChE 58 Delafloxacin 58 potency selectivity 58 PLK1 SNALP 58 GAP #B# 58 class anticancer quinolone 58 secretory phospholipase A2 sPLA2 58 Azedra ™ 58 trastuzumab DM1 58 direct thrombin inhibitors 58 RECOTHROM R 58 ® natalizumab 58 preclinically 58 ARRY # 58 Temsirolimus 58 PEGPH# 58 polymerase inhibitor 58 novel immunomodulatory 58 taxane chemotherapy 58 Phase 1a clinical 58 inhaled iloprost 58 ApoB SNALP 58 haematological malignancies 58 BrachySil TM 58 elacytarabine 58 bevacizumab Avastin R 58 Sapacitabine 58 angiogenesis inhibitor 58 agonist compounds 58 Ceflatonin 58 Zemiva TM 58 mapatumumab 58 genotypic resistance 58 liposome formulation 58 fuel cells SOFCs 58 PEGylated Fab fragment 58 Ophena TM 58 class proteasome inhibitor 58 BCR ABL inhibitors 58 isatoribine 58 elotuzumab 58 Sulonex TM 58 Xcytrin R 58 Aganocide 58 targeted antifolate 58 BiTE 58 Olaparib 58 alefacept 58 Vaxfectin R 58 seliciclib CYC# 58 delipidation 58 BRIM2 58 MTP inhibitor 58 VersaFilm 58 Initiate Phase 58 investigational HCV polymerase 58 hyaluronidase enzyme 58 maturation inhibitor 58 pharmacodynamic profile 58 Chemophase 58 concurrent chemoradiation 58 folate analogue metabolic 58 Personalized Immunotherapy 58 oral isotype selective HDAC 58 REGN# 58 DACH platinum 58 atacicept 58 mTOR inhibitors 58 generation nucleoside analog 58 generation URAT1 inhibitor 58 telaprevir VX 58 Atu# 58 vitro ADME 58 MAb 58 MORAb 58 M2 subunit 58 Adenoscan R 58 ProSavin 58 oral PTH 58 ON #.Na 58 JAK2 inhibitor 58 REP# 58 dasatinib Sprycel ® 58 MVA BN R 58 XmAb ® 58 M1 muscarinic 58 luliconazole 58 subcutaneous PRO 58 orally dosed 58 tolerability profiles 58 IMC #B 58 Aplidin R 58 ulimorelin 58 ularitide 58 chemopreventive agents 58 compound PMX # 58 sorafenib Nexavar 58 non nucleoside 58 TEMSO 58 Lu AA# 58 SCH # 58 beta 1a 58 treat refractory angina 58 5 HT4 receptor 58 CCR9 58 Azedra TM 58 pharmacodynamic markers 58 dopamine D2 58 ACTEMRA TM 58 fosbretabulin 58 Imprime PGG ® 58 trastuzumab emtansine T DM1 58 PEG PAL 58 Aliskiren 58 specific lectin receptors 58 PXD# 58 XL# XL# XL# XL# 58 ALN HPN 58 antiproliferative effects 58 CYP#A# CYP#D# 58 Adnectin 58 investigational pan BCR 58 myelofibrosis polycythemia vera 58 highly selective endothelin 58 lapatinib Tykerb 58 preclinical toxicology 58 Elagolix 58 tyrosine kinase inhibitor TKI 58 Vectibix panitumumab 58 Lodamin 58 N chlorinated antimicrobial 58 cytoprotective 58 Trastuzumab DM1 58 targeted tyrosine kinase 58 Vidaza azacitidine 58 proteasome inhibitors 58 Ocrelizumab 58 selective immunoproteasome inhibitor 58 relapsed refractory multiple myeloma 58 Amplimexon 58 Phase Ib clinical 58 CG# [003] 58 siRNA conjugates 58 2 methoxyestradiol 58 anti angiogenic drugs 58 MET amplification 58 Troxatyl 58 NB S# strontium malonate 58 oxaliplatin Eloxatin 58 Aurora Kinase 58 cetuximab Erbitux 58 Insegia 58 dimebon latrepirdine 58 trodusquemine 58 THR beta agonist 58 Zyclara 58 apoptosis inducers 58 ATRA IV 58 kinase inhibitor 58 LE SN# 58 anti amnesic 58 RhuDex ® 58 Zoraxel 58 Kinase Inhibitor 58 SGLT 58 lymphoid malignancies 58 Crofelemer budesonide foam 58 NR2B selective 58 Tumour Vascular Disrupting Agent 58 Cerashield 58 cannabinor 58 molecular imaging radiopharmaceuticals 58 Daclizumab 58 SIRT1 activators 58 PCK# 58 rALLy 58 evaluating picoplatin 58 thymidylate synthase TS 58 MKC# MKC# PP 58 GelSite R polymer 58 chemically modified siRNA 58 JAK3 58 myeloproliferative diseases 58 Elvitegravir 58 vascular disrupting agents 58 basal insulins 58 Epanova 58 THALOMID 58 candidates Azedra TM 57 Phase 1b clinical trials 57 proprietary BiTE ® 57 UPLYSO 57 somatostatin receptor 57 TKB# 57 selectively inhibited 57 tubulin inhibitors 57 Phase #b/#a trial 57 anti angiogenic agent 57 PKC# 57 Plicera 57 GAMMAGARD 57 oral bioavailability 57 initiate Phase 1b 57 Radezolid 57 Shigamabs ® 57 topical gel formulation 57 Anticalin R 57 Phase 2b clinical trials 57 humanized anti 57 oral dosage 57 DOS# 57 endothelin antagonist 57 ZEVALIN ® 57 EOquin TM 57 IL# PE#QQR 57 RiVax 57 CINOD 57 gallium containing 57 JAK1 57 vivo preclinical 57 polysaccharide polymer 57 Matrix Phase 2b 57 inhibiting tumor 57 cyclophilin inhibitor 57 Targretin capsules 57 phase IIb III 57 Proxinium TM 57 huN# DM1 57 Miraxion Amarin lead 57 Trofex 57 PF # [002] 57 Exherin TM 57 AQ4N 57 Traficet EN 57 Benlysta belimumab 57 antiangiogenic 57 Ophena 57 investigational protease inhibitor 57 potently inhibit 57 Lenocta 57 GEM OS2 57 statistically significant efficacy 57 PDX pralatrexate 57 linear pharmacokinetics 57 AzaSite Plus 57 include VALSTAR TM 57 humanized monoclonal antibody 57 Trodusquemine 57 poly ADP ribose polymerase 57 Pruvel ™ 57 NS5B polymerase 57 irinotecan hydrochloride 57 JAK3 inhibitor 57 Romidepsin 57 HIV integrase inhibitors 57 antifolate 57 tanespimycin 57 Dapagliflozin 57 Initiated Phase 57 nitric oxide donating prostaglandin 57 EDEMA3 trial 57 Aganocide TM 57 GLYX 57 product candidate Lpathomab 57 candidate XP# 57 DU #b 57 RH1 57 Factor VIIa Factor VIII 57 Elotuzumab 57 compound AEZS 57 olaparib 57 Bicifadine 57 GW# [003] 57 PEGylated 57 Fibroblast Growth Factor Receptor 57 investigational compounds 57 hypoxia activated prodrug 57 ADP receptor antagonist 57 EZN 57 XP# XP# 57 Pharmos pipeline 57 antitumor effects 57 defensin mimetic antibiotic 57 IIa trials 57 Nanobody 57 Varespladib 57 reslizumab 57 antimetastatic activity 57 dextromethorphan quinidine 57 generation purine nucleoside 57 AeroLEF TM 57 non nucleoside polymerase 57 Initiate Clinical Trial 57 oral ridaforolimus 57 CoFactor 57 BAY #-# 57 Genasense ® oblimersen 57 epigenetic therapies 57 LEP ETU 57 TLK# 57 OTCBB PYTO 57 FVIIa 57 small molecule activators 57 topical antifungal 57 phase Ib 57 heparanase 57 factor Xa inhibitor 57 Budesonide foam crofelemer 57 Phase 1b trial 57 ganaxolone 57 initiate Phase 2b 57 Phase 2a clinical trials 57 generation FBPase inhibitor 57 Triapine 57 Proellex TM 57 Octreotide 57 signal transduction inhibitor 57 prucalopride 57 humanised antibody 57 Phase 1b clinical 57 riboflavin vitamin B2 57 Cloretazine 57 inhibited tumor 57 VIBEX MTX 57 Quinamed R 57 Solulin 57 GetGoal Phase III 57 Systemic Delivery 57 oblimersen 57 immunomodulatory therapy 57 proprietary polysaccharide 57 telomerase inhibitor 57 torezolid phosphate 57 velafermin 57 synthetic retinoid 57 potently inhibits 57 ponatinib 57 oral nucleoside analogue 57 ALB # 57 recombinant PSMA vaccine 57 CytoFabTM 57 Tamibarotene 57 JVRS 57 APOPTONE 57 pharmacokinetic PK study 57 LEVAQUIN ® 57 IRX 2 57 Copegus ribavirin 57 ProLindac TM 57 Etoposide 57 Tarvacin 57 systemically administered 57 Valdoxan 57 polymerase inhibitors 57 anti CD3 57 Aganocide ® 57 PEGylated irinotecan 57 glucagon receptor 57 oral ghrelin agonist 57 RNAi therapeutic targeting 57 nitric oxide donating 57 sargramostim 57 SYN# 57 candidate iSONEP TM 57 ZFN modified 57 inhibitor PPI 57 MGCD# [001] 57 tezampanel 57 Initiates Clinical 57 adhesion molecule EpCAM expressing 57 Afatinib 57 SAR# [002] 57 cystinosis patients 57 TLR7 agonist 57 apremilast 57 octreotide acetate 57 exacerbations multiple sclerosis 57 Cephalon Oncology 57 INTEGRILIN R eptifibatide Injection 57 Serdaxin 57 topical ophthalmic 57 adenosine injection 57 iobenguane 57 Evoltra ® 57 vitro potency 57 antineoplastic 57 metastatic castration resistant 57 PTK# 57 extraction SPE 57 ALN VSP 57 retaspimycin 57 BCR ABL inhibitor 57 UVIDEM 57 ANAVEX #-# [002] 57 Exherin 57 Anticalin 57 ARIKACE ™ 57 LY# [003] 57 trans retinoic acid ATRA 57 CA9 SCAN 57 ostarine 57 RezularTM 57 NSABP C 57 Crizotinib 57 MNTX 57 pharmacogenomic translational research 57 CLORETAZINE TM VNP#M 57 SUTENT ® 57 MetAP2 57 favorable pharmacokinetic 57 brentuximab vedotin SGN 57 PROSTASCINT R 57 evaluating Prochymal 57 Pruvel 57 Synavive 57 Completes Patient Enrollment 57 beta lactam 57 HuMax CD# 57 vitro cytotoxicity 57 acetonide FA 57 brivaracetam 57 Anticalins R 57 HDAC Inhibitor 57 JAK#/JAK# inhibitor CYT# 57 chemopreventive agent 57 novel topoisomerase 57 BrachySil 57 tolevamer 57 MEK Inhibitor 57 VEGF inhibitor 57 Flt3 57 oral salmon calcitonin 57 liposome encapsulated 57 VitiGam 57 peptidic